Dermata Therapeutics Stock Target Price and Analyst Consensus
| DRMA Stock | USD 0.36 0.02 5.88% |
The current analyst and expert consensus on Dermata Therapeutics is Buy, with no strong buy opinions. The current projected Dermata Therapeutics target price consensus is 90.00 with 1 analyst opinions. The most common way Dermata Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Dermata Therapeutics executives and customers to further validate their buy or sell advice. Please note, the number of analysts providing the opinion is not sufficient to provide adequate consensus on Dermata Therapeutics. We encourage you to use your own analysis of Dermata Therapeutics to validate this buy or sell advice. Dermata Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected Dermata Therapeutics target price to derive its highest and lowest estimates based on its projected price volatility. Check out Macroaxis Advice on Dermata Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.
Lowest Forecast 81.9 | Highest Forecast 99.9 | Target Price 90 |
Dermata |
It's important to approach Dermata Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Dermata Therapeutics price targets
Dermata Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using Dermata Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at Dermata Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Dermata Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Dermata Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Dermata Therapeutics is a key component of Dermata Therapeutics valuation and have some predictive power on the future returns of a Dermata Therapeutics.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Dermata Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Business Services Invested over 100 shares | |
 | Driverless Cars Invested over 60 shares | |
Check out Macroaxis Advice on Dermata Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Dermata Stock analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
The data published in Dermata Therapeutics' official financial statements usually reflect Dermata Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Dermata Therapeutics. For example, before you start analyzing numbers published by Dermata accountants, it's critical to develop an understanding of what Dermata Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Dermata Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Dermata Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Dermata Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Dermata Therapeutics. Please utilize our Beneish M Score to check the likelihood of Dermata Therapeutics' management manipulating its earnings.